Urethral Stricture Treatment Market Insights
Urethral strictures can be caused by diagnostic or therapeutic urological procedures. As a result of the increasing geriatric population, these demand for these procedures is also increasing. Therefore, prevalence of urethral strictures is expected to become more common over the forecast period. Urethral stricture is more prevalent in men than in females. According to data published by the National Centers for Biotechnology & Information (NCBI) in January 2016, the prevalence of urethral stricture is around 200 per 100,000 in males below 65 years in the U.S.
The global urethral stricture treatment market is estimated to be valued at US$ 1,326.0 million in 2019, and is expected to exhibit a CAGR of 6.0% during the forecast period (2019–2027).
Figure 1. Global Urethral Stricture Treatment Market Share (%), By Type, (2019 & 2027)
Source: Coherent Market Insights Analysis (2019)
Increasing incidence of prostate cancer, injuries, and medical conditions requiring urethral stents, dilators, and catheters is expected to drive growth of the market over the forecast period
According to data published by the National Centers for Biotechnology & Information (NCBI), urethral stricture is a common disease with prevalence of over 400 per 100,000 males across the globe in 2016. According to Cancer Research UK, prostate cancer is the most common cancer with around 47,200 new cases registered in 2015 among males in the U.K. Moreover, the incidence of prostate cancer is projected to increase by 12% between 2014 and 2035, to 233 cases per 100,000 males by 2035 in the U.K., as per Cancer Research UK. Therefore, the rising incidences of urethral stricture is expected to drive growth of the market.
In addition to increasing incidence of urethral stricture, the high success rate of the procedure is also expected to facilitate growth of the urethroplasty segment during the forecast period. For instance, according to the British Association of Urological Surgeons (BAUS) Limited, urethroplasty is the most preferred procedure for treatment of urethral strictures and has a success rate of over 85.0% compared to other procedures
Global Urethral Stricture Treatment Market- Restraints
Urethral stricture treatment requires highly efficient & technologically advanced procedures. Technologically advanced procedures offer fast recovery with no down time and reduce recurrence. However, high cost of surgical procedures is likely to hamper growth of the market as individuals in lower middle income economies may not be able to afford the treatment. According to the Elsevier Inc. the cost of first treatment of Direct Vision Internal Urethrotomy (DVIU) is US$ 3,375.0 and the cost of second term treatment of DVIU is US$ 7,522.5, which is very expensive for patients in low and middle income countries.
Global Urethral Stricture Treatment Market- Regional Analysis
Regional segmentation of the global urethral stricture treatment market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among regions, North America is estimated to exhibit significant growth in the urethral stricture treatment market, owing to presence of key players such as Becton, Dickinson and Company (Bard Medical), Cook Medical, and Teleflex Incorporated offering innovative ureteral stents. Moreover, increasing incidence and prevalence of urethral stricture in the region is expected to contribute to growth of the North America urethral stricture treatment market during the forecast period. The diagnosis rate of urethral strictures is expected to increase with age, prostatic hyperplasia, peripheral vascular disease, and hypogonadism. For instance, in 2018, according to reports published in the Journal of Urology, around 1% of men in the U.S. were diagnosed with urethral stricture.
Moreover, increasing demand for efficient and advanced techniques for treatment of urethral strictures in the region is expected to drive growth of the market during the forecast period. For instance, in July 2018, UroTiss Europe GmbH developed an innovative therapeutic option in tissue engineering called MukoCell, a graft for urethroplasty, which helps to replace and avoid complications associated with the native oral mucosa sections.
Furthermore, the Asia Pacific urethral stricture treatment market is expected to hold significant market share during the forecast period owing to increasing incidence of urethral strictures and increasing strategic collaborations between research institutes for development of novel treatments. In November 2018, researchers from Japan and India collaborated together for development of a new treatment method for male urethral stricture.
Figure 2: Global Urethral Stricture Treatment Market Share (%), By Region, (2019 & 2027)
Source: Coherent Market Insights Analysis (2019)
Global Urethral Stricture Treatment Market- Competitive Landscape
Key players operating in the urethral stricture treatment market include Becton, Dickinson and Company, Amecath, Zhejiang Chuangxiang, Medical Technology Co., Ltd, Allium Ltd., SURGIMEDIK, Cook Group, Taewoong Medical Co., Ltd., Teleflex Incorporated, B. Braun Melsungen AG, Coloplast A/S, Boston Scientific Corporation, and Pnn Medical A/S.